MRK logo
MRK
Merck

Aging Populations And Biotech Breakthroughs Will Drive Expansion

AN
AnalystHighTarget
AnalystHighTarget
Not Invested
Consensus Narrative from 24 Analysts
Published
20 Apr 25
Updated
06 Aug 25
AnalystHighTarget's Fair Value
US$127.59
37.7% undervalued intrinsic discount
06 Aug
US$79.44
Loading
1Y
-29.4%
7D
-2.8%

Author's Valuation

US$127.6

37.7% undervalued intrinsic discount

AnalystHighTarget Fair Value

Narrative
Updates3

Shared on07 May 25
Fair value Decreased 9.60%

Read more

Shared on30 Apr 25
Fair value Increased 4.23%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Increased 5.01%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Read more